LATEST ONCOPRESCRIBE UPDATES
FDA Approves RYBREVANT® in Combination with Chemotherapy for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
FDA Approves OPDIVO® in Combination with Chemotherapy for the First Line Treatment of Advanced Urothelial Carcinoma
Stockholm3 Blood Test Identifies Aggressive Prostate Cancer
FDA Approves ONIVYDE® for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
Circulating Tumor DNA Can be Used as an Early Marker of Immunotherapy Response
Late Breaking Abstract – 2024 ASCO GU Cancers Symposium: Adjuvant KEYTRUDA® Improves Overall Survival in Renal cell Carcinoma
Pregnancy after Breast Cancer Treatment in BRCA Carriers
Late Breaking Abstract – 2024 ASCO GU Cancers Symposium: Subcutaneous Nivolumab Offers Efficiency and Efficacy in Renal Cell Carcinoma